08:26 AM EDT, 03/13/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Wednesday it opened a phase 3 trial evaluating Bretzri Aerosphere as treatment for severe cardiopulmonary outcomes in people with chronic lung disease.

Also, AstraZeneca ( AZN ) said it has dosed the first patients of a separate phase 3 trial that evaluates Bretzri on parameters related to the heart and lungs, such as hyperinflation and exercise endurance time.

Price: 67.29, Change: -0.11, Percent Change: -0.16